Transcript Document

Chapter 85: Treatment and
Prevention of Bone
Metastases and Myeloma
Bone Disease
Jean-Jacques Body
From the Primer on the Metabolic Bone Diseases
and Disorders of Mineral Metabolism, 7th Edition.
www.asbmrprimer.org
Figure 1
Figure 1 Analgesic activity of long-term therapy with bisphosphonates in placebo-controlled trials. Effects
of zoledronic acid (Zole) are shown in left panels (pain assessed by the Brief Pain Inventory score,
quantitative 10-point scale): top, breast cancer; bottom, prostate cancer. Effects of ibandronate (Iban) in
breast cancer are shown in the right panels (pain assessed on a qualitative five-point scale): top,
intravenous route; bottom, oral route.
© 2008 American Society for Bone and Mineral Research
From the Primer on the Metabolic Bone Diseases
and Disorders of Mineral Metabolism, 7th Edition.
www.asbmrprimer.org
Figure 2
Figure 2 Effects of long-term therapy with bisphosphonates on the risk of developing a skeletal
complication in patients with bone metastases. Data are summarized by a multiple-event analysis
(Andersen-Gill model for zoledronic acid and Poisson regression analysis for ibandronate). Hazard ratios
(and 95% CI) are shown in the left part of each graph with corresponding p values indicated in the right
parts.
© 2008 American Society for Bone and Mineral Research